Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma
- PMID: 20944103
Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma
Abstract
Background/aim: To examine the presence of macrophage migration inhibitory factor (MIF) quantitatively in relation to neoplastic progression of hypopharyngeal squamous cell carcinoma (HSCC).
Materials and methods: The presence of MIF was analysed by quantitative immunohistochemistry in sections of 81 HSCCs, and compared to 15 specimens of tumour-free epithelia (TF_E), 29 low-grade dysplasias (Low_D) and 25 high-grade dysplasias (High_D). In parallel, MIF expression was studied using Western blotting on a series of 19 fresh biopsies.
Results: A significant increase in MIF staining intensity (mean optical density) was observed in carcinoma samples compared to TF_E (p<10(-6)), Low_D (p=0.0006) or High_D (p=0.0006). Immunohistochemical MIF positivity was significantly higher in HSCCs than in TF_E (p=0.00001) or Low_D (p=0.001). The percentage of MIF-immunopositive cells (labelling index) significantly decreased in parallel with an apparent loss of histological differentiation (p=0.003).
Conclusion: This study identified the presence of MIF as a parameter that positively correlates with neoplastic progression of HSCC and cell differentiation status.
Similar articles
-
Galectin-3 upregulation during tumor progression in head and neck cancer.Laryngoscope. 2008 Sep;118(9):1583-90. doi: 10.1097/MLG.0b013e31817b0718. Laryngoscope. 2008. PMID: 18677282
-
Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas.Histopathology. 2008 Mar;52(4):483-93. doi: 10.1111/j.1365-2559.2008.02973.x. Histopathology. 2008. PMID: 18315601
-
Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bile acids and NSAIDs.Carcinogenesis. 2005 Jan;26(1):11-5. doi: 10.1093/carcin/bgh279. Epub 2004 Sep 9. Carcinogenesis. 2005. PMID: 15358635
-
Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance.Clin Cancer Res. 2002 Dec;8(12):3755-60. Clin Cancer Res. 2002. PMID: 12473586
-
Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma.Cancer. 2005 Feb 1;103(3):588-98. doi: 10.1002/cncr.20818. Cancer. 2005. PMID: 15612021
Cited by
-
Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies.J Cancer Res Clin Oncol. 2013 May;139(5):727-37. doi: 10.1007/s00432-013-1375-7. Epub 2013 Jan 25. J Cancer Res Clin Oncol. 2013. PMID: 23354841 Free PMC article.
-
Involvement of CD74 in head and neck squamous cell carcinomas.J Cancer Res Clin Oncol. 2014 Jun;140(6):937-47. doi: 10.1007/s00432-014-1648-9. Epub 2014 Mar 25. J Cancer Res Clin Oncol. 2014. PMID: 24663824 Free PMC article.
-
Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer.Oncol Rep. 2014 Aug;32(2):523-9. doi: 10.3892/or.2014.3272. Epub 2014 Jun 16. Oncol Rep. 2014. PMID: 24939415 Free PMC article.
-
HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.Cell Death Dis. 2014 Jan 2;5(1):e980. doi: 10.1038/cddis.2013.508. Cell Death Dis. 2014. PMID: 24384723 Free PMC article.
-
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.J Exp Med. 2012 Feb 13;209(2):275-89. doi: 10.1084/jem.20111117. Epub 2012 Jan 23. J Exp Med. 2012. PMID: 22271573 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous